Novartis AG agreed to buy Cadent Therapeutics, a U.S. developer of treatments for cognitive and mood disorders, for as much as $770 million, amid a recent wave of acquisitions in the pharmaceutical industry.
https://www.bloomberg.com/news/articles/2020-12-17/novartis-to-buy-cadent-therapeutics-for-up-to-770-million